Investor Presentation First Nine Months of 2022

49 Investor presentation First nine months of 2022 Novo Nordisk global insulin market leadership at 46.8% and the global insulin volume market grew by 0.5% North America Operations Market growth: -1.4% MS: 38.2% MS gain/loss¹: -1.0%-p Sales growth: -20% USA Market growth: -1.4% MS: 37.7% MS gain/loss: -1.1%-p Sales growth: -22% Global Market growth: 0.5% MS 46.8% MS gain/loss': -0.5%-p Sales growth: -11%: Novo NordiskⓇ International Operations Market growth: 1.2% MS: 49.9% MS gain/loss: -0.4%-p Sales growth: -7% Market growth: -3.5% MS: 57.1% MS gain/loss': -0.4%-p Sales growth: 3% Region China Market growth: 7.6% MS: 49.5% MS gain/loss¹: -1.3%-p Sales growth: -21% EMEA Market growth: 1% MS: 47.6% ROW MS gain/loss: 0.0%-p Sales growth: -2% Source: IQVIA MAT, Aug 2022 volume figures Note: Sales growth for first nine months of 2022 at constant exchange rates; Market shares are for Novo Nordisk, market growth for total insulin market 1MS gain/loss compared with Aug 2021 reported MS EMEA: Europe, Middle East and Africa; MS: Market share; ROW: Asia Pacific; Latin America; MS: Market Share; Region China covers Mainland China, Taiwan, and Hong Kong

View entire presentation